Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule quinazoline derivative featuring a tert-butyl-substituted phenylthio group at the 5-position and diamino groups at the 2 and 4 positions of the quinazoline core. It is a potent inhibitor of dihydrofolate reductase (DHFR), an enzyme critical for folate metabolism and DNA synthesis. The compound has demonstrated nanomolar inhibitory activity against yeast DHFR (IC50 ~8 nM) and micromolar activity against human DHFR (IC50 ~2000 nM). Its primary mechanism is competitive inhibition of DHFR by binding to its active site. This class of compounds is often explored for potential antitumor or antimicrobial properties due to their ability to disrupt nucleotide biosynthesis[3][1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-[4-tert-butylphenylsulfanyl]-2,4-quinazolinediamine.